Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Barclays Downgrades Zoopla To Equal Weight

Thu, 21st Apr 2016 08:31

LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday:
----------
FTSE 100
----------
JEFFERIES RAISES LAND SECURITIES PRICE TARGET TO 975 (957) PENCE - 'HOLD'
----------
JEFFERIES CUTS INTU PROPERTIES PRICE TARGET TO 240 (247) PENCE - 'UNDERPERFORM'
----------
JEFFERIES CUTS HAMMERSON PRICE TARGET TO 473 (493) PENCE - 'UNDERPERFORM'
----------
JEFFERIES CUTS BRITISH LAND PRICE TARGET TO 570 (615) PENCE - 'UNDERPERFORM'
----------
EXANE BNP RAISES GLAXOSMITHKLINE PRICE TARGET TO 1430 (1350) PENCE - 'NEUTRAL'
----------
MORGAN STANLEY RAISES GLAXOSMITHKLINE PRICE TARGET TO 1500 (1450) PENCE - 'EQUALWEIGHT'
----------
CITIGROUP RAISES ARM HOLDINGS PRICE TARGET TO 1060 (1045) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES BHP BILLITON PRICE TARGET TO 780 (665) PENCE - 'UNDERWEIGHT'
----------
HSBC RAISES SHELL PRICE TARGET TO 2000 (1925) PENCE - 'BUY'
----------
HSBC RAISES BP PRICE TARGET TO 410 (405) PENCE - 'BUY'
----------
GOLDMAN RAISES BUNZL PRICE TARGET TO 1800 (1780) PENCE - 'SELL'
----------
GOLDMAN RAISES RECKITT BENCKISER PRICE TARGET TO 6680 (6640) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES WOLSELEY PRICE TARGET TO 4400 (4300) PENCE - 'BUY'
----------
CHARLES STANLEY RAISES AB FOODS TO 'HOLD' ('REDUCE')
----------
MORGAN STANLEY RAISES SAGE GROUP PRICE TARGET TO 470 (440)P - 'UNDERWEIGHT'
----------
FTSE 250
----------
BARCLAYS CUTS ZOOPLA TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 295 (270) PENCE
----------
PANMURE CUTS AVEVA GROUP PRICE TARGET TO 1864 (1910) PENCE - 'HOLD'
----------
MORGAN STANLEY RAISES AVEVA GROUP TARGET TO 1,240 (1,150)P - 'UNDERWEIGHT'
----------
JEFFERIES CUTS WORKSPACE GROUP PRICE TARGET TO 765 (804) PENCE - 'HOLD'
----------
JEFFERIES RAISES UNITE GROUP PRICE TARGET TO 575 (569) PENCE - 'HOLD'
----------
JEFFERIES RAISES SHAFTESBURY PRICE TARGET TO 888 (801) PENCE - 'HOLD'
----------
JEFFERIES CUTS SEGRO PRICE TARGET TO 380 (414) PENCE - 'HOLD'
----------
JEFFERIES RAISES LONDONMETRIC PROPERTY PRICE TARGET TO 165 (153) PENCE - 'HOLD'
----------
JEFFERIES CUTS HANSTEEN PRICE TARGET TO 110 (115) PENCE - 'HOLD'
----------
JEFFERIES CUTS GREAT PORTLAND PRICE TARGET TO 668 (705) PENCE - 'HOLD'
----------
JEFFERIES CUTS GRAINGER PRICE TARGET TO 215 (240) PENCE - 'HOLD'
----------
JEFFERIES CUTS DERWENT LONDON PRICE TARGET TO 2950 (3055) PENCE - 'HOLD'
----------
JEFFERIES RAISES BIG YELLOW GROUP PRICE TARGET TO 725 (654) PENCE - 'HOLD'
----------
JEFFERIES CUTS PETROFAC TO 'HOLD' ('BUY')
----------
CREDIT SUISSE RAISES SERCO GROUP PRICE TARGET TO 100 (95) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS VICTREX TO 'HOLD' ('BUY') - TARGET 1620 (1800) PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.